Please login to the form below

Not currently logged in
Email:
Password:

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

Bruno Strigini NovartisNovartis has named Merck & Co's Bruno Strigini as its new president of oncology.

Strigini spent almost five years as president, Europe and Canada, at Merck, which he joined after the company took over Schering Plough where he served in a similar role.

He will now lead an oncology division at Novartis that achieved revenues of more than $10bn during 2013, as seen on PMLiVE's Top Pharma List. These sales made Novartis the third largest pharma company in cancer for the year.

The company has ambitions to expand in the therapy area, however, and recently acquired the bulk of GlaxoSmithKline's cancer portfolio in an asset swap deal valued at $16bn.

Strigini shares these ambitions and in a recent interview with PMLiVE cited oncology as one of the most important growth areas for the industry due, in part, to the potential of immunotherapies.

“When you see what's happening in immuno-oncology today, it's amazing the progress that science is making in the area of oncology,” he said. “That's why I'm optimistic.”

Novartis' interests in immuno-oncology include a research deal with the University of Pennsylvania to focus on novel T-cell immunotherapies and the acquisition of CoStim and its pipeline of oncology candidates, including an ant-PD1 drug.

The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own products.

Leading the field though is Strigini's former company Merck & Co, which has already filed MK-3475 in the US to treat advanced melanoma.

3rd June 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...